<DOC>
	<DOC>NCT00986401</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XRâ„¢) and metformin hydrochloride (Glucophage) when co-administered.</brief_summary>
	<brief_title>Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Trospium chloride</mesh_term>
	<criteria>Weight within +/30% of ideal body weight for height and frame size Nonsmoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 1 months prior to the screening visit). Willing to abstain from caffeinecontaining food and beverages for 24hours prior to dosing, alcoholcontaining food and beverage for 48 hours prior to dosing, and Seville oranges (eg orange marmalade), grapefruit, or grapefruit juice for 7 days prior to the dosing and abstain from all throughout the study. Willing to abstain from taking medications (with the exception of hormonal contraceptives) and nonprescription medication including vitamins, food supplements, and herbal preparations for 7 days prior to Day1 of the first treatment period and throughout the study. Uncontrolled systemic disease Known allergy or sensitivity to the study medication(s) (Trospium, Metformin)or its components Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study. History of myasthenia gravis or closedangle glaucoma. Considering or scheduled to undergo any surgical procedure during the study. History of alcohol or substance abuse within 1 year prior to Day1 of the first treatment period. History of serious mental or physical illness. Donated in excess of 500 mL of blood in the 30 days prior to the screening visit. Required treatment with any medications, either prescription or nonprescription (including vitamins, antacids, acidreducers, food supplements, and herbal preparations, excluding hormonal contraceptives), within 7 days prior to Day1 of the first treatment period during the study. Had an acute illness within 5 days prior to Day1 of the treatment period. Had a history of hepatitis B or C, a positive test for hepatitis B surface antigen, hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies. Planned radiologic study requiring intravenous contrast administration of iodinated contrast material during the study period Serum Creatinine greater than 1.4 mg/dL.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Adults</keyword>
</DOC>